Analysts Set Bausch Health Companies Inc. (NYSE:BHC) Target Price at $7.42

Shares of Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) have earned an average recommendation of "Reduce" from the seven brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and six have issued a hold rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $7.42.

A number of brokerages recently weighed in on BHC. Wall Street Zen cut Bausch Health Companies from a "buy" rating to a "hold" rating in a research note on Saturday, May 10th. Royal Bank of Canada lifted their price target on Bausch Health Companies from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd.

Bausch Health Companies Trading Up 9.2%

BHC stock traded up $0.51 during trading hours on Friday, hitting $6.02. 11,490,808 shares of the stock traded hands, compared to its average volume of 2,611,854. The stock has a 50-day simple moving average of $4.85 and a 200 day simple moving average of $6.42. Bausch Health Companies has a one year low of $3.96 and a one year high of $9.85. The company has a market cap of $2.23 billion, a P/E ratio of -50.12, a P/E/G ratio of 0.37 and a beta of 0.28.

Insiders Place Their Bets

In other Bausch Health Companies news, Director John Paulson acquired 754,134 shares of the firm's stock in a transaction on Tuesday, June 10th. The stock was purchased at an average cost of $5.05 per share, for a total transaction of $3,808,376.70. Following the transaction, the director now owns 27,193,169 shares of the company's stock, valued at $137,325,503.45. The trade was a 2.85% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders acquired 2,788,608 shares of company stock worth $14,700,257. 8.05% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Bausch Health Companies

Institutional investors have recently bought and sold shares of the business. Cary Street Partners Financial LLC acquired a new stake in Bausch Health Companies during the 1st quarter worth about $27,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Bausch Health Companies during the 1st quarter valued at about $27,000. SBI Securities Co. Ltd. lifted its holdings in shares of Bausch Health Companies by 244.2% during the 1st quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock valued at $27,000 after buying an additional 3,001 shares during the last quarter. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Bausch Health Companies during the 4th quarter valued at about $56,000. Finally, Wealthquest Corp acquired a new stake in shares of Bausch Health Companies during the 1st quarter valued at about $58,000. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.